Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | JMJD6 | Q6NYC1 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2668105 | 0.84 | RAB9A (0.51) | TSHRRAB9ANPC1JMJD6ALDH1A1 | |
| SCHEMBL10817921 | 0.77 | TSHR (0.60) | TSHRRAB9ANPC1JMJD6ALDH1A1 | |
| SCHEMBL7515477 | 0.75 | JMJD6 (0.53) | TSHRRAB9ANPC1JMJD6ALDH1A1 | |
| SCHEMBL10154470 | 0.74 | JMJD6 (0.56) | TSHRRAB9ANPC1JMJD6ALDH1A1 | |
| SCHEMBL28894543 | 0.73 | MAPT (0.54) | TSHRALDH1A1 | |
| SCHEMBL5768786 | 0.72 | MEN1 (0.51) | TSHRRAB9ANPC1JMJD6ALDH1A1 | |
| SCHEMBL22005555 | 0.71 | TSHR (0.65) | TSHRRAB9ANPC1JMJD6ALDH1A1 | |
| SCHEMBL8011676 | 0.70 | SMN1; SMN2 (0.45) | TSHRRAB9ANPC1JMJD6ALDH1A1 | |
| SCHEMBL2629432 | 0.70 | TSHR (0.51) | TSHRRAB9ANPC1JMJD6ALDH1A1 | |
| SCHEMBL12448172 | 0.69 | RAB9A (0.50) | TSHRRAB9ANPC1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273777-B2 | Glucokinase activators and methods of using same | BRISTOL-MEYER SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| US-20100324071-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-12-23 | — | — | US | disclosed |
| US-7812048-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090030046-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324071-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, HK1 | TSHR 1000/4885RAB9A 1180/4885NPC1 3627/4885 |
| US-20090030046-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, HK1 | TSHR 1000/4885RAB9A 1180/4885NPC1 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.